Type to search

Aelis Farma Announces the Success of its Initial Public Offering and Raises Approximately €25 Million on Euronext Paris | Pharmtech Focus
Aelis Farma Announces Good Results From its First Administration in Humans for AEF0217, its First Drug Candidate for the Treatment of Cognitive Disorders in Down Syndrome | Pharmtech Focus